
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
| Open | 794.95 |
| High | 808.00 |
| Low | 784.20 |
| Prev Close | 789.90 |
| Volume | 63,546 |
| VWAP(₹) | 793.55 |
| PE Ratio(x) | -21.74 |
| EPS - TTM(₹) | -36.31 |
| MCap(₹ Cr.) | 1,759.07 |
| MCap Rank | 16 |
| PB Ratio(x) | 4.50 |
| Div Yield(%) | - |
| Face Value(₹) | 10.00 |
| 52W High(₹) | 984.85 |
| 52W Low(₹) | 513.40 |
| MCap/Sales | 2.68 |
| Beta(1 Month) | 0.20 |
| BV/Share(₹) | 175.44 |
Losing Shareholder's Money
Company has reported a negative ROE for 3 consecutive years. (Source: Consolidated Financials)PAT: Troublesome Times
Company has posted a loss of Rs 7.76 cr for the 4th consecutive quarter. (Source: Consolidated Financials)Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 17.13% outperformed its 3 year CAGR of -10.82%. (Source: Consolidated Financials)Employee & Interest Expense
Company has spent 7.7% of its operating revenues towards interest expenses and 14.04% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)Astec Lifesc Share Price Update
Astec Lifesciences Ltd. share price moved down by -0.06% from its previous close of Rs 789.90. Astec Lifesciences Ltd. stock last traded price is 789.45
| Share Price | Value |
|---|---|
| Today/Current/Last | 789.45 |
| Previous Day | 789.90 |
Found Insights useful?
| 1 Day | -0.06% |
| 1 Month | 16.82% |
| 3 Months | 34.85% |
| 1 Year | 3.07% |
| 3 Years | -42.66% |
| 5 Years | -40.5% |
1 Analysts
| Ratings | Current | 1W Ago | 1M Ago | 3M Ago |
|---|---|---|---|---|
| Strong Buy | - | - | - | - |
| Buy | - | - | - | - |
| Hold | - | - | - | - |
| Sell | 1 | 1 | 1 | 1 |
| Strong Sell | - | - | - | - |
| # Analysts | 1 | 1 | 1 | 1 |
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | |
|---|---|---|---|---|---|
| Total Income | 161.26 | 125.54 | 74.84 | 91.59 | 120.32 |
| Total Income Growth (%) | 28.45 | 67.75 | -18.29 | -23.88 | 25.63 |
| Total Expenses | 161.23 | 134.05 | 90.85 | 113.56 | 125.58 |
| Total Expenses Growth (%) | 20.28 | 47.55 | -20.00 | -9.57 | 13.13 |
| EBIT | 0.02 | -8.51 | -16.01 | -21.97 | -5.26 |
| EBIT Growth (%) | - | - | - | - | - |
| Profit after Tax (PAT) | -7.76 | -15.70 | -24.43 | -33.04 | -16.09 |
| PAT Growth (%) | - | - | - | - | - |
| EBIT Margin (%) | 0.01 | -6.78 | -21.39 | -23.99 | -4.37 |
| Net Profit Margin (%) | -4.81 | -12.50 | -32.64 | -36.07 | -13.37 |
| Basic EPS (₹) | -3.48 | -7.04 | -11.35 | -16.85 | -8.20 |
All figures in Rs Cr, unless mentioned otherwise
PAT: Troublesome Times
Company has posted a loss of Rs 7.76 cr for the 4th consecutive quarter. (Source: Consolidated Financials)Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 17.13% outperformed its 3 year CAGR of -10.82%. (Source: Consolidated Financials)| Annual | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Total Assets | 942.04 | 881.42 | 974.93 | 979.41 | 896.76 |
| Total Assets Growth (%) | 6.88 | -9.59 | -0.46 | 9.22 | 32.35 |
| Total Liabilities | 551.12 | 646.41 | 605.41 | 559.86 | 500.10 |
| Total Liabilities Growth (%) | -14.74 | 6.77 | 8.14 | 11.95 | 35.80 |
| Total Equity | 390.92 | 235.02 | 369.52 | 419.56 | 396.66 |
| Total Equity Growth (%) | 66.34 | -36.40 | -11.93 | 5.77 | 28.24 |
| Current Ratio (x) | 0.89 | 0.93 | 1.00 | 0.95 | 1.05 |
| Total Debt to Equity (x) | 1.15 | 2.36 | 1.34 | 0.81 | 0.70 |
| Contingent Liabilities | 0.00 | 161.06 | 213.66 | 256.17 | 239.82 |
All figures in Rs Cr, unless mentioned otherwise
| Annual | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Net Cash flow from Operating Activities | -80.71 | -8.40 | 10.22 | 74.66 | 23.60 |
| Net Cash used in Investing Activities | -4.31 | -15.23 | -135.18 | -112.51 | -103.87 |
| Net Cash flow from Financing Activities | 94.49 | 23.73 | 124.96 | 37.77 | 80.48 |
| Net Cash Flow | 9.47 | 0.10 | 0.00 | -0.08 | 0.22 |
| Closing Cash & Cash Equivalent | 10.05 | 0.58 | 0.47 | 0.47 | 0.55 |
| Closing Cash & Cash Equivalent Growth (%) | 1,646.44 | 22.04 | -0.40 | -14.63 | 48.86 |
| Total Debt/ CFO (x) | -5.56 | -66.03 | 48.32 | 4.57 | 11.84 |
All figures in Rs Cr, unless mentioned otherwise
Decrease in Cash from Investing
Company has used Rs 4.31 cr for investing activities which is an YoY decrease of 71.73%. (Source: Consolidated Financials)| Annual | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Return on Equity (%) | -20.71 | -57.40 | -12.70 | 6.09 | 22.66 |
| Return on Capital Employed (%) | -10.03 | -20.22 | -6.32 | 12.28 | 32.05 |
| Return on Assets (%) | -8.58 | -15.28 | -4.81 | 2.61 | 10.02 |
| Interest Coverage Ratio (x) | 0.02 | -1.65 | -0.01 | 4.31 | 18.17 |
| Asset Turnover Ratio (x) | 0.49 | 0.41 | 0.47 | 0.67 | 0.86 |
| Price to Earnings (x) | -14.86 | -9.82 | -44.44 | 106.38 | 38.31 |
| Price to Book (x) | 3.08 | 5.64 | 5.64 | 6.46 | 8.66 |
| EV/EBITDA (x) | 3,007.70 | -30.96 | -9,580.53 | 34.14 | 22.56 |
| EBITDA Margin (%) | 0.12 | -15.88 | -0.05 | 14.21 | 24.31 |
Losing Shareholder's Money
Company has reported a negative ROE for 3 consecutive years. (Source: Consolidated Financials)Found Financials useful?
No Data Available
No Data Available
| R1 | - | Pivot - | S1 | - |
| R2 | - | S2 | - | |
| R3 | - | S3 | - |
| 5 Days | 14 Days | 28 Days |
| - | - | - |
Choose from Peers
Choose from Stocks
MF Ownership as on 31 May 2026
40.62
Amount Invested (in Cr.)
0.05%
% of AUM
0.00
% Change (MoM basis)
9.90
Amount Invested (in Cr.)
0.24758638%
% of AUM
0.00
% Change (MoM basis)
1.40
Amount Invested (in Cr.)
0.0179219%
% of AUM
0.00
% Change (MoM basis)
General Meeting
-
Jun 03, 2026
General Meeting
-
May 04, 2026
Board Meeting
Audited Results
Apr 20, 2026
| Announced on | Meeting on |
| Apr 20, 2026 | Apr 27, 2026 |
| Audited Results | |
| Jan 20, 2026 | Jan 30, 2026 |
| Quarterly Results | |
| Oct 14, 2025 | Oct 29, 2025 |
| Quarterly Results | |
| Jul 11, 2025 | Jul 28, 2025 |
| Quarterly Results | |
| Jun 25, 2025 | Jun 30, 2025 |
| Right Issue of Equity Shares | |
| Announced on | Ex-Date | Dividend% |
| May 02, 2023 | Jul 21, 2023 | 15% |
| May 02, 2022 | Jul 19, 2022 | 15% |
| Apr 30, 2021 | Jul 22, 2021 | 15% |
| May 05, 2020 | Jul 16, 2020 | 15% |
| Apr 30, 2019 | Jul 18, 2019 | 15% |
No Data Available
No Data Available
| Announced on | Ex-Date |
| Jun 24, 2025 | Jul 04, 2025 |
| Rights ratio: 1 share for every 7 held at a price of Rs 890.0 | |
| Announced on | Meeting on |
| Jun 03, 2026 | Jul 06, 2026 |
| - | |
| May 04, 2026 | Jul 31, 2026 |
| - | |
| Apr 28, 2025 | Jun 01, 2025 |
| - | |
| Apr 23, 2025 | Jul 28, 2025 |
| - | |
| Feb 11, 2025 | Mar 18, 2025 |
| - | |
Astec Lifesciences Ltd., incorporated in the year 1994, is a Small Cap company (having a market cap of Rs 1,759.07 Crore) operating in Pesticides/Agro Chemicals sector.
Industry
Key Indices Listed On
BSE SmallCap, BSE Commodities, BSE AllCap, BSE Next 250 Microcap, BSE NEXT 500
Address
Godrej One, 3rd Floor,Pirojshanagar,Eastern Express Highway,Mumbai, Maharashtra - 400079
Nadir B Godrej
ChairmanBurjis N Godrej
Managing DirectorAshok V Hiremath
Non Executive DirectorBalram Singh Yadav
Non Executive DirectorDATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.